Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis

Figure 4

Genes differentially expressed at baseline between poor versus moderate and good responders to adalimumab therapy. Five hundred twenty-four genes were found to be differentially expressed among good, moderate, and poor responders at baseline by analysis of variance (P < 0.05). Post hoc (Student-Newman-Keuls) tests were used to discriminate genes that were specifically upregulated (n = 411) or downregulated (n = 28) in poor responders as compared with the two other groups. Pathway analyses indicated that these genes were significantly enriched in genes involved in the regulation of immune responses (a) and genes involved in cell division (b).

Back to article page
\